Related Experiment Videos
Autoantibodies in scleroderma and polymyositis: an update
1Division of Rheumatology, Immunology, and Allergy, University of Oklahoma Health Science Center, Oklahoma City.
Seminars in Dermatology
|September 1, 1991
Summary
Autoantibodies detected through indirect immunofluorescence are key for diagnosing systemic connective tissue diseases like scleroderma. Further analysis refines diagnostic and prognostic autoantibody identification efficiently.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Cutaneous symptoms of systemic connective tissue diseases (CTDs) frequently lead to early dermatologic evaluation.
- Indirect immunofluorescent autoantibody tests using tissue culture substrates serve as initial screening for CTDs.
- These tests show high positivity in scleroderma and its variants, but lower positivity in polymyositis and dermatomyositis.
Purpose of the Study:
- To summarize major autoantibody specificities in systemic connective tissue diseases.
- To emphasize current concepts of clinical, molecular, and pathogenetic significance of these autoantibodies.
- To highlight efficient and cost-effective autoantibody definition through combined testing strategies.
Main Methods:
- Initial screening via indirect immunofluorescent autoantibody determinations on tissue culture substrates.
- Second-level analyses for precipitin autoantibodies.
- Review of major autoantibody specificities characteristic of CTDs.
Main Results:
- High positivity rates of autoantibodies in scleroderma and its variants.
- Lower positivity rates in polymyositis and dermatomyositis.
- Efficient and cost-effective definition of diagnostically and prognostically significant autoantibodies when combining screening and second-level tests.
Conclusions:
- Autoantibody profiling is crucial for diagnosing and understanding systemic connective tissue diseases.
- Combined autoantibody testing strategies offer efficient and cost-effective diagnostic and prognostic insights.
- Further research into the clinical, molecular, and pathogenetic significance of autoantibodies is warranted.